• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
COVID-19 discharge and follow-up recommendations.新型冠状病毒肺炎出院及随访建议。
Proc (Bayl Univ Med Cent). 2020 Oct 30;34(1):73-75. doi: 10.1080/08998280.2020.1834341.
2
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者：快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
3
Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment.伴有和不伴有神经系统受累的 SARS-CoV-2/COVID-19 住院患者的长期结局：3 年随访评估。
PLoS Med. 2024 Apr 4;21(4):e1004263. doi: 10.1371/journal.pmed.1004263. eCollection 2024 Apr.
4
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究：一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
5
Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version).《COVID-19 的化学预防、诊断、治疗和出院管理：基于证据的临床实践指南（更新版）》
Mil Med Res. 2020 Sep 4;7(1):41. doi: 10.1186/s40779-020-00270-8.
6
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
7
Universal testing for severe acute respiratory syndrome coronavirus 2 in 2 Philadelphia hospitals: carrier prevalence and symptom development over 2 weeks.在费城的 2 家医院进行的严重急性呼吸综合征冠状病毒 2 通用检测：2 周内的携带者流行率和症状发展。
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100226. doi: 10.1016/j.ajogmf.2020.100226. Epub 2020 Sep 11.
8
Seizures in febrile children with SARS-CoV-2 infection: clinical features, short-term follow-up.伴有 SARS-CoV-2 感染的热性惊厥儿童：临床特征、短期随访。
BMC Pediatr. 2024 Apr 17;24(1):257. doi: 10.1186/s12887-024-04691-5.
9
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性（COVA 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
10
Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City, Zhejiang, China.中国浙江省温州市出院 COVID-19 患者的胸部计算机断层扫描和临床随访。
Ann Am Thorac Soc. 2020 Oct;17(10):1231-1237. doi: 10.1513/AnnalsATS.202004-324OC.

引用本文的文献

1
Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study.Janus激酶抑制剂在长新冠疾病所致肺部受累管理中的作用：一项病例对照研究。
Turk J Emerg Med. 2023 Jun 26;23(3):149-155. doi: 10.4103/tjem.tjem_363_22. eCollection 2023 Jul-Sep.
2
Antidiabetic Treatment before Hospitalization and Admission Parameters in Patients with Type 2 Diabetes, Obesity, and SARS-CoV-2 Viral Infection.2型糖尿病、肥胖症和SARS-CoV-2病毒感染患者住院前的抗糖尿病治疗及入院参数
J Pers Med. 2023 Feb 23;13(3):392. doi: 10.3390/jpm13030392.
3
Evaluation of Blood Biochemistry and Cardiopulmonary status of Hospitalized Covid-19 Patients in 3 Months Post Discharged Follow up Survey.出院后3个月随访调查中住院新冠肺炎患者的血液生化和心肺状况评估
Clin Med Insights Circ Respir Pulm Med. 2022 Dec 22;16:11795484221119332. doi: 10.1177/11795484221119332. eCollection 2022.
4
The utility of telemedicine in managing patients after COVID-19.远程医疗在管理 COVID-19 后患者中的应用。
Sci Rep. 2022 Dec 10;12(1):21392. doi: 10.1038/s41598-022-25348-2.
5
[Cardiorespiratory and neuromusculoskeletal symptoms with post-acute COVID-19 in a Rehabilitation center].[康复中心中急性 COVID-19 后出现的心肺和神经肌肉骨骼症状]
Rev Med Inst Mex Seguro Soc. 2022 Jul 4;60(4):395-401.
6
Clinical analysis on diagnostic accuracy of Bosch Vivalytic SARS-CoV-2 point-of-care test and evaluation of cycle threshold at admission for COVID-19 risk assessment.博世 Vivality SARS-CoV-2 即时检测诊断准确性的临床分析及入院时循环阈值对 COVID-19 风险评估的评价。
BMC Infect Dis. 2022 May 23;22(1):486. doi: 10.1186/s12879-022-07447-7.
7
New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago.芝加哥大都市地区新冠肺炎住院后新的家庭补充氧气疗法。
ERJ Open Res. 2022 Mar 21;8(1). doi: 10.1183/23120541.00577-2021. eCollection 2022 Jan.
8
Post-hospitalization venous thromboembolism in COVID-19 patients: Evidence against routine post-hospitalization prophylactic anticoagulation.新冠病毒感染患者出院后静脉血栓栓塞：反对常规出院后预防性抗凝治疗的证据
Int J Lab Hematol. 2022 Feb;44(1):e4-e7. doi: 10.1111/ijlh.13633. Epub 2021 Jun 19.

本文引用的文献

1
Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report.新型冠状病毒肺炎患者静脉血栓栓塞症的预防、诊断和治疗：CHEST 指南和专家报告。
Chest. 2020 Sep;158(3):1143-1163. doi: 10.1016/j.chest.2020.05.559. Epub 2020 Jun 2.
2
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.改良的IMPROVE VTE风险评分与升高的D-二聚体可识别急性病患者群体中高静脉血栓栓塞风险，以进行延长的血栓预防。
TH Open. 2020 Mar 13;4(1):e59-e65. doi: 10.1055/s-0040-1705137. eCollection 2020 Jan.
3
Post-Hospitalization Short-Term Oxygen Therapy: Use of a Clinical Management Pathway and Long-Term Follow-Up.住院后短期氧疗：临床管理路径的应用和长期随访。
Respir Care. 2019 Mar;64(3):272-278. doi: 10.4187/respcare.06303. Epub 2018 Nov 6.
4
Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions.阿司匹林与全关节置换术后静脉血栓栓塞的预防：常见问题
Bone Joint J. 2017 Nov;99-B(11):1420-1430. doi: 10.1302/0301-620X.99B11.BJJ-2017-0337.R2.

新型冠状病毒肺炎出院及随访建议。

COVID-19 discharge and follow-up recommendations.

作者信息

Abdelnabi Mahmoud, Leelaviwat Natnicha, Eshak Nouran, Mekraksakit Poemlarp, Nugent Kenneth, Payne J Drew

机构信息

Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, Alexandria University, Alexandria, Egypt.

Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

出版信息

Proc (Bayl Univ Med Cent). 2020 Oct 30;34(1):73-75. doi: 10.1080/08998280.2020.1834341.

DOI:10.1080/08998280.2020.1834341
PMID:33456149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7785155/
Abstract

Currently, the world is facing a global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19. So far, there are no clear recommendations regarding hospital discharge and aftercare for COVID-19. Here, we briefly discuss the current understanding of recommendations for discharge criteria, discharge treatment regimens, and follow-up.

摘要

目前，全球正面临由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的全球大流行，该病毒也被称为新冠病毒。到目前为止，关于新冠病毒感染者的出院标准及出院后护理尚无明确建议。在此，我们简要讨论一下目前对出院标准、出院治疗方案及随访建议的理解。